|
|
|
MIRA INFORM REPORT
|
Report No. : |
493490 |
|
Report Date : |
27.02.2018 |
IDENTIFICATION DETAILS
|
Name : |
CAPSUGEL
US, INC. |
|
|
|
|
Registered Office : |
412 Mount Kemble Avenue Suite
200-C Morristown, NJ 07960 |
|
|
|
|
Country : |
United States |
|
|
|
|
Financials (as on) : |
2016 (Summarised) |
|
|
|
|
Date of Incorporation : |
1931 |
|
|
|
|
Legal Form : |
Corporation |
|
|
|
|
Line of Business : |
Subject is engaged in
manufactures and sells drug capsules, sells equipment for filling empty and
liquid capsules, as well as equipment for sealing liquid capsules. |
|
|
|
|
No. of Employees : |
2,000 |
RATING & COMMENTS
(Mira Inform has adopted New Rating mechanism w.e.f. 23rd
January 2017)
|
MIRA’s Rating : |
B |
|
Credit Rating |
Explanation |
Rating Comments |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
Status : |
Moderate |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
NOTES :
Any query related to this report can be made
on e-mail : infodept@mirainform.com
while quoting report number, name and date.
ECGC Country Risk Classification List
|
Country Name |
Previous Rating (30.09.2017) |
Current Rating (31.12.2017) |
|
United States |
A1 |
A1 |
|
Risk Category |
ECGC
Classification |
|
Insignificant |
A1 |
|
Low Risk |
A2 |
|
Moderately Low Risk |
B1 |
|
Moderate Risk |
B2 |
|
Moderately High Risk |
C1 |
|
High Risk |
C2 |
|
Very High Risk |
D |
UNITED STATES - ECONOMIC OVERVIEW
The US has the most technologically powerful economy in the world, with a per capita GDP of $57,300. US firms are at or near the forefront in technological advances, especially in computers, pharmaceuticals, and medical, aerospace, and military equipment; however, their advantage has narrowed since the end of World War II. Based on a comparison of GDP measured at purchasing power parity conversion rates, the US economy in 2014, having stood as the largest in the world for more than a century, slipped into second place behind China, which has more than tripled the US growth rate for each year of the past four decades.
In the US, private individuals and business firms make most of the decisions, and the federal and state governments buy needed goods and services predominantly in the private marketplace. US business firms enjoy greater flexibility than their counterparts in Western Europe and Japan in decisions to expand capital plant, to lay off surplus workers, and to develop new products. At the same time, businesses face higher barriers to enter their rivals' home markets than foreign firms face entering US markets.
Long-term problems for the US include stagnation of wages for lower-income families, inadequate investment in deteriorating infrastructure, rapidly rising medical and pension costs of an aging population, energy shortages, and sizable current account and budget deficits.
The onrush of technology has been a driving factor in the gradual development of a "two-tier" labor market in which those at the bottom lack the education and the professional/technical skills of those at the top and, more and more, fail to get comparable pay raises, health insurance coverage, and other benefits. But the globalization of trade, and especially the rise of low-wage producers such as China, has put additional downward pressure on wages and upward pressure on the return to capital. Since 1975, practically all the gains in household income have gone to the top 20% of households. Since 1996, dividends and capital gains have grown faster than wages or any other category of after-tax income.
Imported oil accounts for nearly 55% of US consumption and oil has a major impact on the overall health of the economy. Crude oil prices doubled between 2001 and 2006, the year home prices peaked; higher gasoline prices ate into consumers' budgets and many individuals fell behind in their mortgage payments. Oil prices climbed another 50% between 2006 and 2008, and bank foreclosures more than doubled in the same period. Besides dampening the housing market, soaring oil prices caused a drop in the value of the dollar and a deterioration in the US merchandise trade deficit, which peaked at $840 billion in 2008. Because the US economy is energy-intensive, falling oil prices since 2013 have alleviated many of the problems the earlier increases had created.
The sub-prime mortgage crisis, falling home prices, investment bank failures, tight credit, and the global economic downturn pushed the US into a recession by mid-2008. GDP contracted until the third quarter of 2009, making this the deepest and longest downturn since the Great Depression. To help stabilize financial markets, the US Congress established a $700 billion Troubled Asset Relief Program (TARP) in October 2008. The government used some of these funds to purchase equity in US banks and industrial corporations, much of which had been returned to the government by early 2011. In January 2009, Congress passed and President Barack OBAMA signed a bill providing an additional $787 billion fiscal stimulus to be used over 10 years - two-thirds on additional spending and one-third on tax cuts - to create jobs and to help the economy recover. In 2010 and 2011, the federal budget deficit reached nearly 9% of GDP. In 2012, the Federal Government reduced the growth of spending and the deficit shrank to 7.6% of GDP. US revenues from taxes and other sources are lower, as a percentage of GDP, than those of most other countries.
Wars in Iraq and Afghanistan required major shifts in national resources from civilian to military purposes and contributed to the growth of the budget deficit and public debt. Through 2014, the direct costs of the wars totaled more than $1.5 trillion, according to US Government figures.
In March 2010, President OBAMA signed into law the Patient Protection and Affordable Care Act, a health insurance reform that was designed to extend coverage to an additional 32 million Americans by 2016, through private health insurance for the general population and Medicaid for the impoverished. Total spending on healthcare - public plus private - rose from 9.0% of GDP in 1980 to 17.9% in 2010.
In July 2010, the president signed the DODD-FRANK Wall Street Reform and Consumer Protection Act, a law designed to promote financial stability by protecting consumers from financial abuses, ending taxpayer bailouts of financial firms, dealing with troubled banks that are "too big to fail," and improving accountability and transparency in the financial system - in particular, by requiring certain financial derivatives to be traded in markets that are subject to government regulation and oversight.
In December 2012, the Federal Reserve Board (Fed) announced plans to purchase $85 billion per month of mortgage-backed and Treasury securities in an effort to hold down long-term interest rates, and to keep short-term rates near zero until unemployment dropped below 6.5% or inflation rose above 2.5%. In late 2013, the Fed announced that it would begin scaling back long-term bond purchases to $75 billion per month in January 2014 and further reduce them as conditions warranted; the Fed ended the purchases during the summer of 2014. In 2014, the unemployment rate dropped to 6.2%, and continued to fall to 5.5% by mid-2015, the lowest rate of joblessness since before the global recession began; inflation stood at 1.7%, and public debt as a share of GDP continued to decline, following several years of increases. In December 2015, the Fed raised its target for the benchmark federal funds rate by 0.25%, the first increase since the recession began. With US GDP growth below 2%, the Fed opted to raise rates three times since then, and in mid-June 2017, the range for the target rate stood at 1% to 1.25%.
|
Source
: CIA |
STATUTORY
INFORMATION
|
|
|
|
|
|
Legal Name: |
CAPSUGEL US, INC. |
|
Trade Name: |
CAPSUGEL |
|
ID: |
4992036 |
|
Date Created: |
1931 |
|
Date Incorporated: |
6/3/2011 |
|
Legal Address: |
Registered Agent The Corporation Trust Company Corporation Trust Center 1209
Orange St Wilmington, New Castle De, 19801 USA |
|
Operative Address: |
412 Mount Kemble Avenue Suite 200-C Morristown, NJ 07960 United States |
|
Telephone: |
(862) 242-1700 |
|
Fax: |
(862) 242-1700 |
|
Legal Form: |
Corporation |
|
Email: |
info@capsugel.com solutions@capsugel.com privacyofficer@lonza.com |
|
Registered in: |
DELAWARE |
|
Website: |
www.capsugel.com |
|
Contact: |
Guido Edouard Driesen, Chief
Executive Officer and President John L. Shroyer, Chief
Financial Officer |
|
Staff: |
2,000 |
|
Activity: |
NAICS 1: Pharmaceutical
Preparation Manufacturing SIC 1: Antibiotics, Packaged |
|
|
|
BANKS
|
|
|
|
The company does not make its banking data
public |
|
|
|
HISTORY
|
|
|
|
Capsugel was founded in 1931 in
Detroit, Michigan as a division of Parke-Davis, after Arthur Colton designed
a machine which simultaneously manufactured the body and caps of a hard
gelatin capsule, and fit them together. |
|
Key Developments: |
In 1970, Parke-Davis, including
Capsugel, was acquired by Warner Lambert, which was acquired by Pfizer in
2000. On 1 August 2011, Pfizer sold Capsugel to global investment firm
Kohlberg Kravis Roberts for $2.38 billion. In July 2017, the Lonza Group
completed the acquisition of Capsugel for $5.5 billion from Kohlberg Kravis
Roberts. Lonza-Capsugel Presents at
ProBiota 2018, Feb-08-2018 01:00 PM Feb 5 18 Lonza-Capsugel Presents at
ProBiota 2018, Feb-08-2018 01:00 PM. Venue: Plaza
España, 6-8. 08014, Barcelona, Spain. Speakers: Morgan Laloux, Business Development Manager. Capsugel Announces Availability
of its Modular Automated Sampling Technology (Mast) System Feb 8 17 Capsugel announced the broad
commercial availability of its Modular Automated Sampling Technology (MAST)
system, which directly transfers samples from bioreactors to analytical
devices while maintaining process sterility. This first-of-its-kind
technology allows aseptic collection of accurate, representative samples that
generate detailed process information in real-time. MAST represents the
latest innovation developed by Capsugel to address biopharmaceutical product
development and processing challenges MAST provides a modular system that is
readily scalable and suitable for use throughout the product development
process. The system instantaneously provides a wide range of information at
the molecular level for media, cells and bioreactor products, allowing for
rapid response to maintain optimum bioreactor conditions and maximize yields.
The commercial availability of the technology is the culmination of a focused
five-year program conducted by Capsugel's Bend, Ore. facility, in
collaboration with several of the biopharmaceutical companies. The company
has also developed alliances with numerous analytical equipment suppliers to
facilitate process analytical technology (PAT) integration into bioprocessing
through MAST. MAST provides for tailored system design and can be readily
expanded with additional sampling modules as required. MASTconnect™ software
allows for configurable, flexible and user-friendly operation of the MAST
system, with special modules for sample scheduling, sample navigation and
analytical data management. Lonza And KKR In Talks To
Acquire Capsugel For $5 Billion. Dec 12 16 Lonza Group Ltd (SWX:LONN) on
Monday confirmed that it is in advanced talks with private equity firm KKR
& Co. L.P. (NYSE:KKR) to acquire Capsugel Inc. Potential transaction
would be valued at more than $5 billion. |
|
|
|
PRINCIPAL
ACTIVITY
|
|
|
Capsugel, Inc. is a large-sized
organization in the pharmaceutical preparation companies industry located in
Morristown, NJ. Capsugel is a company that manufactures and sells drug
capsules. Capsugel also sells equipment for filling empty and liquid
capsules, as well as equipment for sealing liquid capsules. |
|
|
Products/Services description: |
Capsugel Inc. develops dosage
forms and solutions for the healthcare industry around the world. It offers
gelatin, alternate polymer, and liquid-filled capsules; hard gelatin, sprinkle,
plus HPMC, fish gelatin, pearlescent, over-encapsulation, pre-clinical,
liquid, soft gelatin, acid-resistant capsules; gelcaps; capsule in capsule
technology products; and solid lipid pellet technology products. The company
also provides precision powder micro-dosing systems, CFS liquid filling and
sealing machines, profill manual capsule filling machines, and commercial
scale capsule filling machines. The company develops drug delivery technology
platform, enTRinsic, that offers enteric protection without the requirement
of functional coatings. Its product applications include drug compounds,
liquid-filled products, vegetarian products, over-encapsulation, dry powder
inhaler capsules, targeted release, low moisture capsules, taste and odor
masking, health and nutrition, line extensions, and product differentiation.
In addition, it offers services, which include dosage form development, abuse
deterrent dosage form development, colonic dosage form development
formulation support, lipid expert system, pre-clinical and clinical support,
manufacturing and technical services, quality management support, and
regulatory assistance. Capsugel Inc. has strategic partnerships with Cardax,
Inc. and Pulmatrix, Inc. |
|
Brands: |
NA |
|
Sales are: |
Wholesale |
|
Clients: |
Unichem Laboratories Limited India Granules India Limited. India Farmacid Sa Ecuador Capsugel De Mexico S De Rl De Cv Mexico |
|
Suppliers: |
Capsugel De Mexico S De Rl De Cv Mexico CAPSUGEL JAPAN INC. Japan |
|
Operations area: |
National and International |
|
The company imports from |
Mexico and Japan |
|
The company exports to |
Worldwide |
|
The subject employs |
2,000 employees |
|
Payments: |
No Complaints |
|
|
|
LOCATION
|
|
|
Headquarters : |
412 Mount Kemble Avenue Suite 200-C Morristown, NJ 07960 United States |
|
Comments: |
NA |
|
Branches: |
Capsugel, while headquartered
in the United States, has bases in 12 countries. Capsugel's corporate
headquarters are in Morristown, New Jersey. BEND, OREGON, USA 1201 NW Wall Street, Suite 200 Bend, OR 97703 Telephone: 541-382-4100 Fax: 541-382-2713 QUAKERTOWN, PENNSYLVANIA, USA Powdersize 20 Pacific Dr. Quakertown, PA 18951 Telephone: 215-536-5605 TAMPA, FLORIDA, USA Xcelience Inc. 4910 Savarese Circle Tampa, FL 33634 Telephone: 1-813-286-0404 Fax: 1-813-675-0179 GREENWOOD, SOUTH CAROLINA, USA Customer Service: 800-845-6973
(toll free) Customer Inquiry: 888-783-6361
(toll free) Capsugel 535 North Emerald Road Greenwood, SC 29646 Telephone: 888-783-6381 Fax: 888-783-6360 |
|
Main Competitors |
Pernix Therapeutics, Llc 10 N Park Pl Ste 201 Omniactive Health Technlogies,
Inc. 67 E Park Pl Ste 500 Orexo Us, Inc. 150 Hadquarters Plz E Twr |
|
Related Companies: |
Capsugel has research and
development labs in: Illkirch, France Greenwood, South Carolina Colmar, France Bornem, Belgium Tampa, Florida It has major production
facilities in: The Americas Greenwood, South Carolina Puebla, Mexico Europe Ploërmel, France Colmar, France Bornem, Belgium Asia Sagamahara, Japan Suzhou, China Dharuhera, India Ayuthaya, Thailand Cibinong, Indonesia |
|
|
|
GROUP
STRUCTURE AND SUBSIDIARY COMPANIES
|
|
|
Listed at the stock exchange: |
NO |
|
Capital: |
NA |
|
Shareholders: |
This is a private company. The company does not
disclose information on shareholders. The following information has been
obtained through private sources and could not be confirmed: As of July 5, 2017, Capsugel Inc. operates as a
subsidiary of: Lonza Group Ltd. Address: Muenchensteinerstrasse 38 Basel 4002 Switzerland Telephone: 41 61 316 81 11 Website: www.lonza.com Full Time Employees: 14,618 |
|
Management: |
Guido Edouard Driesen, Chief Executive Officer and
President John L. Shroyer, Chief Financial Officer Erasmo Schutzer, Chief Marketing Officer and Senior
Vice President Keith Hutchison Ph.D., Senior Vice President of
Research and Development Frank Briamonte, Senior Director of Corporate
Communications |
|
|
|
FINANCIAL
INFORMATION
|
|
|
|
The company does not make its financial statements
public. The following information has been provided by private sources: |
|
|
|
|
USD 2016 |
|
|
Revenue |
250,000,000 |
|
Cash flow |
Normal |
|
|
We also attach the latest financial
statements of Lonza Group Ltd. |
|
LEGAL FILINGS |
|
|
|
|
|
Patents |
SELF-EMULSIFYING FORMULATIONS AND METHODS OF USE
THEREOF Publication number: 20130184290 Abstract: The present invention relates to formulations
and methods for increasing the bioavailability of
1-(4-benzhydrylpiperazin-1-yl)-3,3-diphenylpropan-1-one,
diphenylpropanoyl)piperazine, or a salt thereof. In particular, the
formulation can include one or more self-emulsifying carriers. Type: Application Filed: October 26, 2012 Publication date: July 18, 2013 Applicants: CAPSUGEL, Inc., Zalicus Pharmaceuticals
Ltd. Inventors: Zalicus Pharmaceuticals Ltd., CAPSUGEL,
Inc. |
|
|
|
|
Cases |
No records found |
|
|
|
|
UCC |
No records found |
|
|
|
|
OFAC Sanctions
List Search |
The company is not listed in
the OFAC list. |
|
|
|
SUMMARY
|
|
|
|
Founded in 1931, Capsugel, Inc. is a large-sized
organization in the pharmaceutical preparation companies industry located in Morristown,
NJ. Capsugel is a company that manufactures and sells drug capsules. Capsugel
also sells equipment for filling empty and liquid capsules, as well as
equipment for sealing liquid capsules. The company has 2,000 full-time employees and
generates an estimated USD 250 million in annual revenue. The company imports from Mexico and India, and
exports worldwide, operating within national and international markets. As of July 5, 2017, Capsugel Inc. operates as a
subsidiary of Lonza Group Ltd. This has been an ACTIVE company incorporated in
DELAWARE in 2011. |
|
|
|
RISK
INFORMATION
|
|
|
|
|
|
DEBTS |
Controlled |
|
PAYMENTS |
No Complaints |
|
CASH FLOW |
Normal |
|
STATUS |
ACTIVE |
|
|
|
INTERVIEW
|
|
|
NAME |
NA |
|
POSITION |
NA |
|
COMMENTS |
Despite we called the company
several times, the person in charge of providing information about the
company was not present, so we could not confirm further information. |
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
INR 64.66 |
|
|
1 |
INR 90.65 |
|
Euro |
1 |
INR 79.69 |
|
USD |
1 |
INR 64.89 |
Note :
Above are approximate rates obtained from sources believed to be correct
INFORMATION DETAILS
|
Analysis Done by
: |
VAR |
|
|
|
|
Report Prepared
by : |
DNS |
RATING EXPLANATIONS
|
Credit Rating |
Explanation |
Rating Comments |
|
A++ |
Minimum Risk |
Business dealings permissible with minimum
risk of default |
|
A+ |
Low Risk |
Business dealings permissible with low
risk of default |
|
A |
Acceptable Risk |
Business dealings permissible with
moderate risk of default |
|
B |
Medium Risk |
Business dealings permissible on a regular
monitoring basis |
|
C |
Medium High Risk |
Business dealings permissible preferably
on secured basis |
|
D |
High Risk |
Business dealing not recommended or on
secured terms only |
|
NB |
New Business |
No recommendation can be done due to
business in infancy stage |
|
NT |
No Trace |
No recommendation can be done as the
business is not traceable |
NB is stated where there is insufficient information to facilitate rating. However, it is not to be considered as unfavourable.
This score serves as a reference to assess
SC’s credit risk and to set the amount of credit to be extended. It is
calculated from a composite of weighted scores obtained from each of the major
sections of this report. The assessed factors are as follows:
·
Financial
condition covering various ratios
·
Company
background and operations size
·
Promoters
/ Management background
·
Payment
record
·
Litigation
against the subject
·
Industry
scenario / competitor analysis
·
Supplier
/ Customer / Banker review (wherever available)
This report is issued at
your request without any risk and responsibility on the part of MIRA INFORM
PRIVATE LIMITED (MIPL) or its officials.